

Swiss edition Data as at end-November 2024 ISIN: LU2054466995


# UBS Digital Transformation Themes Equity Fund USD

## Performance Review

UBS (Lux) Key Selection SICAV - Digital Transformation Themes (USD) (CHF hedged) Q-acc



### Performance (basis CHF, net of fees)<sup>1</sup>



Fund performance net of fees (left-hand scale)
Fund performance per year in % net of fees (right-hand scale)
Index performance (left-hand scale)

## Past performance is not a reliable indicator of future results.

## Performance in % (net of fees)1

in %	2020	2021	2022	2023	2024	LTD3	4 years (	Ø p.a. 4
					YTD2			years
Fund (CHF)	n.a.	11.71	-38.56	37.78	21.00	100.95	20.39	4.75
Benchmark <sup>4</sup>	n.a.	19.46	-18.16	16.65	18.32	97.25	39.88	8.75

The performance shown does not take account of any commissions, entry or exit charges.

- 1 These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset
- Management.
  2 YTD: year-to-date (since beginning of the year)
- 3 LTD: launch-to-date
- 4 Reference Index in currency of share class (without costs)

Unsurprisingly, Donald Trump's decisive victory in the US presidential election in combination with a red sweep was the dominant market driver in November. Due to the prospect of potentially lower taxes and lighter regulation, US equities outperformed other regional markets, which face increased tariff risk.

## Monthly performance

In November the fund performed positively with 5.7%. Stock selection was positive within information technology and financials, while the negative selection in consumer discretionary and industrials detracted. In terms of sector allocation, our positioning in healthcare and materials added value, while our positioning in financials and communication services detracted.

## YTD performance

YTD as of the end of November, the fund has delivered a positive performance of 21.0%. Growth continues to outperform value in 2024 to date, which is a tailwind to relative performance, as are positive stock selection and sector allocation.

### **Performance contributors**

HubSpot shares rose after the release of strong Q3 results due to robust subscription performance and operating margin expansion, in addition to an increase in full-year guidance. Shopify rallied on the back of its earnings release, as earnings beat expectations thanks to resurgent revenues and improved cost efficiencies.

## **Performance detractors**

Our underweight to Tesla detracted from performance due to the positive sentiment surrounding Trump's election and potential benefits for the carmaker. PDD shares sold off after the company's quarterly report fell short of expectations for the top and bottom lines, as intensified competition continued to weigh on results.

For more information UBS Fund Infoline: 0800 899 899

Internet: www.ubs.com/funds Contact your client advisor

## Portfolio management representatives

Eric Garfunkel Peter J. Bye Katie Thompson

# **UBS Digital Transformation Themes Equity Fund USD**

## Thematic Exposure (%)

Fund					
Enabling Technology	35.5				
Digital Data	28.6				
E-Commerce	14.3				
Fintech	7.1				
Security and safety	5.1				
Health Tech	4.6				
Metaverse	3.1				
Cash	■1.3				
Others	0.4				

#### 10 largest equity positions (%)1

3 1 11	
	Fund
NVIDIA Corp	6.0
Microsoft Corp	5.6
Apple Inc	5.5
Amazon.com Inc	4.5
Alphabet Inc	3.2
Meta Platforms Inc	3.1
Taiwan Semiconductor Manufacturing Co Ltd	2.8
HubSpot Inc	2.8
Oracle Corp	2.8
Advanced Micro Devices Inc	2.6
1 This is not a recommendation to hur	v or sell any security

<sup>1</sup> This is not a recommendation to buy or sell any security

#### **Current investment strategy**

We continue to believe we are in the early stages of artificial intelligence and machine learning, of companies creating personalised relationships with their users, and of technology supporting meaningful medical innovation. We have added to selected high-conviction names given the prospect of near-term volatility.

## Risks

The fund invests in equities and may therefore be subject to high volatility. This requires an elevated risk tolerance and capacity. The value of a unit may fall below the purchase price. The value of a unit may be influenced by currency fluctuations. This fund pursues a very active management style. Its performance may therefore deviate considerably from that of a comparable market return. Focusing intentionally on individual sectors may entail additional risks (e.g. lower diversification). Every fund reveals specific risks, a detailed and comprehensive list of risk descriptions can be found in the prospectus. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 8 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-